ENZO BIOCHEM, INC.

Enzo Biochem disclosed in an 8-K (Item 8.01) that it entered agreements effective August 8, 2024 with the Attorneys General of New York, New Jersey and Connecticut resolving inquiries related to a ransomware attack the Company experienced in April 2023 at its Enzo Clinical Labs subsidiary. The Company agreed to pay $4.5 million, divided among the three AGs, and to implement cybersecurity enhancements and an Information Security Program. The Company neither admits nor denies the investigative findings.

Home - Enzo Biochem

Enzo Biochem, Inc. disclosed a ransomware attack on April 6, 2023, impacting IT systems. The incident resulted in the access and exfiltration of clinical test information for approximately 2,470,000 individuals, including Social Security numbers for about 600,000. The company disconnected systems, engaged third-party experts, and notified law enforcement. Investigation and impact assessment were ongoing at the time of filing.

Enzo Biochem, Inc. disclosed a ransomware attack on April 6, 2023, impacting IT systems. The company disconnected systems, engaged third-party experts, and activated its disaster recovery plan. On April 11, 2023, the company confirmed data was extracted. Operations continued via backup processes, though laboratory specimen processing was delayed. Investigation and impact assessment were ongoing at the time of filing.

enzo.com